LivaNova PLC – NASDAQ:LIVN
LivaNova stock price today
$53.59
+7.03
+15.1%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
LivaNova stock price monthly change
-9.47%
month
LivaNova stock price quarterly change
-9.47%
quarter
LivaNova stock price yearly change
-10.80%
year
LivaNova key metrics
Market Cap | 2.54B |
Enterprise value | 2.66B |
P/E | -27.06 |
EV/Sales | 2.61 |
EV/EBITDA | 86.47 |
Price/Sales | 2.25 |
Price/Book | 1.90 |
PEG ratio | -0.67 |
EPS | -0.59 |
Revenue | 1.18B |
EBITDA | 15.80M |
Income | -31.74M |
Revenue Q/Q | 11.96% |
Revenue Y/Y | 13.38% |
Profit margin | -8.44% |
Oper. margin | 5.15% |
Gross margin | 69.21% |
EBIT margin | 5.15% |
EBITDA margin | 1.33% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLivaNova stock price history
LivaNova stock forecast
LivaNova financial statements
Average Price Target
$67
Potential upside: 25.02%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 293.9M | 1.15M | 0.39% |
|---|---|---|---|
| Sep 2023 | 286.1M | -7.3M | -2.55% |
| Dec 2023 | 310.1M | 16.33M | 5.27% |
| Mar 2024 | 294.91M | -41.94M | -14.22% |
| Jun 2023 | 2341600000 | 1.10B | 47.02% |
|---|---|---|---|
| Sep 2023 | 2329400000 | 1.10B | 47.39% |
| Dec 2023 | 2429563000 | 1.15B | 47.41% |
| Mar 2024 | 2459602000 | 1.23B | 50.34% |
| Jun 2023 | -18M | -6.6M | 36M |
|---|---|---|---|
| Sep 2023 | 18.2M | -10.1M | -4.3M |
| Dec 2023 | 53.95M | -12.13M | -5.01M |
| Mar 2024 | 9.98M | -6.36M | 37.14M |
LivaNova alternative data
| Aug 2023 | 2,900 |
|---|---|
| Sep 2023 | 2,900 |
| Oct 2023 | 2,900 |
| Nov 2023 | 2,900 |
| Dec 2023 | 2,900 |
| Jan 2024 | 2,900 |
| Feb 2024 | 2,900 |
| Apr 2024 | 2,900 |
| May 2024 | 2,900 |
| Jun 2024 | 2,900 |
| Jul 2024 | 2,900 |
LivaNova other data
100.00%
0.00%
of LIVN is owned by hedge funds
215
+12
54.96M
+238.64K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 0 | 56623 |
| Sep 2024 | 0 | 1500 |
| Dec 2024 | 0 | 1250 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | HUTCHINSON MICHAEL DAMON officer: Chief Legal Officer | Ordinary Shares | 2,254 | N/A | N/A | ||
Option | HUTCHINSON MICHAEL DAMON officer: Chief Legal Officer | Restricted Stock Units | 2,254 | N/A | N/A | ||
Option | POLETTI FRANCO officer: President, Cardiopulmo.. | Ordinary Shares | 967 | N/A | N/A | ||
Option | BARRY JAMES CHRISTOPHER director | Ordinary Shares | 1,709 | N/A | N/A | ||
Option | BARRY JAMES CHRISTOPHER director | Restricted Stock Units | 1,709 | N/A | N/A | ||
Option | SHVARTSBURG ALEX officer: Chief Fi.. | Ordinary Shares | 613 | N/A | N/A | ||
Option | SHVARTSBURG ALEX officer: Chief Fi.. | Restricted Stock Units | 613 | N/A | N/A | ||
Option | POLETTI FRANCO officer: President, Cardiopulmo.. | Restricted Stock Units | 967 | N/A | N/A | ||
Sale | BIANCHI FRANCESCO director | Ordinary Shares | 1,250 | $50.99 | $63,738 | ||
Sale | BIANCHI FRANCESCO director | Ordinary Shares | 1,500 | $46.58 | $69,870 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 26 Jul 2023 | Q2 2023 Earnings Call Transcript |
LivaNova: Reaching End Of RECOVER And ANTHEM
LivaNova's Neuromodulation Products Could Imply Significant Undervaluation
Why InMode Deserves A Spot In Your 2023 Portfolio
LivaNova Loses Profit Momentum On Higher R&D Expense
LivaNova Matures Into Profitability, Still Waiting On DTD
LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation
Milan Court Decision Does Not Change LivaNova Bullish Story
LivaNova's Peculiar Situation Makes For A Cheap Option
Haemonetics: Buy When There's Blood In The Streets
-
What's the price of LivaNova stock today?
One share of LivaNova stock can currently be purchased for approximately $53.59.
-
When is LivaNova's next earnings date?
Unfortunately, LivaNova's (LIVN) next earnings date is currently unknown.
-
Does LivaNova pay dividends?
No, LivaNova does not pay dividends.
-
How much money does LivaNova make?
LivaNova has a market capitalization of 2.54B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.89% to 1.15B US dollars.
-
What is LivaNova's stock symbol?
LivaNova PLC is traded on the NASDAQ under the ticker symbol "LIVN".
-
What is LivaNova's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of LivaNova?
Shares of LivaNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are LivaNova's key executives?
LivaNova's management team includes the following people:
- Mr. Damien McDonald Chief Executive Officer & Director(age: 60, pay: $1,280,000)
- Mr. Marco Dolci Head of Global Operations and R&D(age: 63, pay: $744,150)
- Ms. Keyna Pidcock Skeffington Senior Vice President, Gen. Counsel & Corporation Sec.(age: 62, pay: $623,280)
- Mr. Alex Shvartsburg Chief Financial Officer and Corporation Vice President of Financial Planning, Analysis & International Region(age: 55, pay: $445,290)
-
How many employees does LivaNova have?
As Jul 2024, LivaNova employs 2,900 workers.
-
When LivaNova went public?
LivaNova PLC is publicly traded company for more then 9 years since IPO on 19 Oct 2015.
-
What is LivaNova's official website?
The official website for LivaNova is livanova.com.
-
How can i contact LivaNova?
LivaNova can be reached via phone at +44 20 3325 0660.
-
What is LivaNova stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for LivaNova in the last 12 months, the avarage price target is $67. The average price target represents a 25.02% change from the last price of $53.59.
LivaNova company profile:
LivaNova PLC
livanova.comExchange:
NASDAQ
Full time employees:
2,900
Industry:
Medical - Devices
Sector:
Healthcare
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
20 Eastbourne Terrace
London, W2 6LG
London, W2 6LG
CIK: 0001639691
ISIN: GB00BYMT0J19
CUSIP: G5509L101
